Novo Nordisk receives updated price targets from major banks

Financial institutions have issued updated outlooks for Novo Nordisk. JPMorgan raised its price target for the company from 250 to 275 Danish kroner, while maintaining a ‘Neutral’ rating. Analyst Richard Vosser increased his 2026 revenue forecast by 5 percent, citing high expectations for the diabetes and weight-loss drug Ozempic.

Separately, Deutsche Bank Research maintained a ‘Hold’ rating for Novo Nordisk with a price target of 290 Danish kroner, following an analysis of weekly prescription data.